ASCO guidance for stage IV EGFR-mutant NSCLC supports initial combination regimens (osimertinib plus chemotherapy; amivantamab plus lazertinib) to improve disease control relative to monotherapy.
New drugs have made America’s deadliest cancer more treatable than ever. So why aren’t they reaching patients? By Simar Bajaj More than half of patients with metastatic lung cancer don’t receive ...
About half of people diagnosed with metastatic non-small-cell lung cancer never receive treatment, despite advances in options over recent decades that have created meaningful improvements in lifespan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results